Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
Raschko JW, Synold TW, Chow W, Coluzzi P, Hamasaki V, Leong LA, Margolin KA, Morgan RJ, Shibata SI, Somlo G, Tetef ML, Yen Y, ter Veer A, Doroshow JH. Raschko JW, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2000;46(5):403-10. doi: 10.1007/s002800000142. Cancer Chemother Pharmacol. 2000. PMID: 11127945 Clinical Trial.
Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells.
Zhou BS, Hsu NY, Pan BC, Doroshow JH, Yen Y. Zhou BS, et al. Among authors: yen y. Cancer Res. 1995 Mar 15;55(6):1328-33. Cancer Res. 1995. PMID: 7882331
It has been shown that a HU-resistant clone derived from stepwise exposure to HU overexpresses the M2 mRNA and the RR protein (Y. Yen et al., Cancer Res., 54: 3868-3691, 1994). In this study, we established stable clones by transfecting human KB cells with the cDNA …
It has been shown that a HU-resistant clone derived from stepwise exposure to HU overexpresses the M2 mRNA and the RR protein (Y. …
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.
Newman EM, Carroll M, Akman SA, Chow W, Coluzzi P, Hamasaki V, Leong LA, Margolin KA, Morgan RJ, Raschko JW, Shibata S, Somlo G, Tetef M, Yen Y, Ahn CW, Doroshow JH. Newman EM, et al. Among authors: yen y. Cancer Chemother Pharmacol. 1997;39(3):254-8. doi: 10.1007/s002800050569. Cancer Chemother Pharmacol. 1997. PMID: 8996529 Clinical Trial.
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
Somlo G, Doroshow JH, Forman SJ, Odom-Maryon T, Lee J, Chow W, Hamasaki V, Leong L, Morgan R Jr, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Simpson J, Molina A. Somlo G, et al. Among authors: yen y. J Clin Oncol. 1997 Aug;15(8):2882-93. doi: 10.1200/JCO.1997.15.8.2882. J Clin Oncol. 1997. PMID: 9256132
Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ Jr, Newman EM, Doroshow JH, McGonigle K, Margolin K, Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B, Yen Y, Klevecz R. Morgan RJ Jr, et al. Among authors: yen y. Cancer Res. 1998 Jul 1;58(13):2793-800. Cancer Res. 1998. PMID: 9661893 Clinical Trial.
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S, Bhatia R, Chow W, Leong L, Morgan R, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Forman S, Jones D, Ashby M, Fyfe G, Hellmann S, Doroshow JH. Somlo G, et al. Among authors: yen y. Blood. 1999 May 1;93(9):2798-806. Blood. 1999. PMID: 10216073 Free article. Clinical Trial.
Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies.
Somlo G, Chow W, Hamasaki V, Leong L, Margolin K, Morgan R Jr, Sniecinski I, Frankel P, Reardon D, Longmate E, Raschko J, Shibata S, O'Donnell M, Smith E, Tetef M, Forman S, Yen Y, Molina A, Doroshow H. Somlo G, et al. Among authors: yen y. Biol Blood Marrow Transplant. 2001;7(5):284-93. doi: 10.1053/bbmt.2001.v7.pm11400951. Biol Blood Marrow Transplant. 2001. PMID: 11400951 Free article. Clinical Trial.
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome.
Somlo G, Doroshow JH, Synold T, Longmate J, Reardon D, Chow W, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Shibata SI, Tetef ML, Yen Y, Kogut N, Schriber J, Alvarnas J. Somlo G, et al. Among authors: yen y. Br J Cancer. 2001 Jun 15;84(12):1591-8. doi: 10.1054/bjoc.2001.1835. Br J Cancer. 2001. PMID: 11401310 Free PMC article. Clinical Trial.
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Morgan RJ, Doroshow JH, Leong L, Schriber J, Shibata S, Forman S, Hamasaki V, Margolin K, Somlo G, Alvarnas J, McNamara M, Longmate J, Raschko J, Chow W, Vasilev S, McGonigle K, Yen Y. Morgan RJ, et al. Among authors: yen y. Bone Marrow Transplant. 2001 Nov;28(9):859-63. doi: 10.1038/sj.bmt.1703243. Bone Marrow Transplant. 2001. PMID: 11781646 Clinical Trial.
1,675 results